|Page (1) of 1 - 04/19/13||email article||print page|
This morning, Deutsche Bank increased its price target on shares of Vertex Pharmaceutical (VRTX) to $100 following news that the company's cystic fibrosis treatment is performing better than expected. Shares of VRTX were sharply higher this morning, gaining more than 55% on the news.
|Analyst Moves: VRTX, NFLX, APH|
Source:GrabNetworks (c). All Rights Reserved